Holen Sie sich die Stockscreener-App
1.82
0.00%
0.00
Handel nachbörslich:
1.82
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ESPR?
Forum
Prognose
Aktiensplit
Esperion Therapeutics Inc Aktie (ESPR) Neueste Nachrichten
Esperion Therapeutics: Little Upside Potential In Their Earlier Generation Drug (NASDAQ:ESPR) - Seeking Alpha
Esperion Therapeutics executive sells shares worth $446 By Investing.com - Investing.com Australia
Esperion Therapeutics (ESPR) to Release Quarterly Earnings on Tuesday - MarketBeat
Esperion Therapeutics CFO sells shares for $20 - Investing.com India
Esperion Therapeutics executive sells shares worth $446 - Investing.com India
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Sees Large Decline in Short Interest - MarketBeat
Zacks Research Has Pessimistic Outlook of ESPR Q3 Earnings - MarketBeat
Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4 - The Manila Times
Esperion Earnings Preview: Key Updates on 14,000-Patient CLEAR Trial & Next-Gen Cardiovascular Pipeline - StockTitan
Esperion Therapeutics (NASDAQ:ESPR) Given "Buy" Rating at HC Wainwright - MarketBeat
JMP Securities Reaffirms Market Outperform Rating for Esperion Therapeutics (NASDAQ:ESPR) - MarketBeat
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Insider Alert: Esperion's Strategic Move58K RSUs Granted to Key New Hires - StockTitan
Esperion stock holds Buy rating, $16 target from H.C. Wainwright - MSN
Esperion stock target cut to $4 by JMP Securities - MSN
Esperion Therapeutics’ (ESPR) Market Outperform Rating Reaffirmed at JMP Securities - Defense World
Esperion stock holds Buy rating, $16 target from H.C. Wainwright By Investing.com - Investing.com Canada
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
ESPR Shares Experience Surge in Value - Knox Daily
SG Americas Securities LLC Increases Stock Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World
What was Esperion Therapeutics Inc (ESPR)’s performance in the last session? - US Post News
Market Resilience: Esperion Therapeutics Inc (ESPR) Finishes Weak at 1.79, Down -1.10 - The Dwinnex
Esperion Therapeutics chief commercial officer sells $277 in stock - MSN
What is HC Wainwright's Estimate for ESPR FY2028 Earnings? - MarketBeat
What is HC Wainwright’s Estimate for ESPR FY2028 Earnings? - Defense World
Esperion Therapeutics’ (ESPR) Buy Rating Reiterated at HC Wainwright - Defense World
JMP Securities maintains $7 target on Esperion stock - MSN
JMP Securities maintains $7 target on Esperion stock By Investing.com - Investing.com Canada
Esperion Therapeutics' (ESPR) "Market Outperform" Rating Reiterated at JMP Securities - MarketBeat
HC Wainwright Reiterates Buy Rating for Esperion Therapeutics (NASDAQ:ESPR) - MarketBeat
Equities Analysts Set Expectations for ESPR FY2025 Earnings - MarketBeat
Cantor Fitzgerald Comments on ESPR FY2025 Earnings - Defense World
Esperion Therapeutics chief commercial officer sells $277 in stock By Investing.com - Investing.com Australia
Esperion Therapeutics CFO sells shares worth $20 By Investing.com - Investing.com South Africa
Esperion Therapeutics CFO sells shares worth $20 - Investing.com India
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Short Interest Update - MarketBeat
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Stock Position Lifted by Barclays PLC - Defense World
Barclays PLC Grows Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat
Esperion stock falls on higher operating expense forecast - MSN
0.92%
1.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):